Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2026)

Neuphoria Therapeutics (NEUP) has reported Total Non-Current Liabilities for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 3.51% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 3.51% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, up 6.99% from the prior year.
• Total Non-Current Liabilities was $2.9 million for Q1 2026 at Neuphoria Therapeutics, down from $4.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $6.7 million in Q3 2025 and troughed at $2.8 million in Q1 2025.
• A 5-year average of $4.3 million and a median of $4.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 62.24% in 2025 and advanced 3.51% in 2026, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $3.6 million in 2022, then increased by 5.99% to $3.8 million in 2023, then declined by 5.68% to $3.6 million in 2024, then climbed by 15.92% to $4.2 million in 2025, then plunged by 30.03% to $2.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.9 million (Q1 2026), $4.2 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.